Prevention of low dose streptozotocin-induced diabetes by acetyl-homocysteine-thiolactone.
G Papaccio
Index: Diabetes Res. Clin. Pract. 13(1-2) , 95-102, (1991)
Full Text: HTML
Abstract
We used acetyl-homocysteine-thiolactone (citiolone) as an enhancer of superoxide dismutase (SOD), a free radical scavenger, in order to assay any possible prevention of the insulitis and subsequent B cell damage caused by streptozotocin (STZ) when given in multiple low doses. Mice were given citiolone (50 mg/kg b.wt.) as a long pretreatment or concomitantly with STZ for a shorter period. Ten days after the last STZ injection, pancreases were processed for SOD assay and morphological observations. Results demonstrate that citiolone increases SOD values, but to a variable degree, after the STZ administration. The highest SOD levels were found in animals treated for the longer period (P less than 0.001 vs saline-treated controls; P less than 0.0001 vs STZ-treated controls) but we did not observe a direct correspondence between high SOD values and morphological integrity of islet beta cells and/or low blood glucose levels. In conclusion, we hypothesize that the onset of type 1 diabetes in mice involves free radical generation but in addition some other factor may be responsible for the beta cell damage.
Related Compounds
Related Articles:
Interleukin-1 beta increases the activity of superoxide dismutase in rat pancreatic islets.
1992-05-01
[Endocrinology 130(5) , 2851-7, (1992)]
Inability of thiol compounds to restore CNS arylsulfatases inhibited by methyl mercury.
1991-07-01
[Pharmacol. Toxicol. 69(1) , 71-4, (1991)]
Recurrent fixed drug eruption caused by citiolone.
1997-01-01
[J. Investig. Allergol. Clin. Immunol. 7(3) , 193-4, (1997)]
1992-07-01
[Bull. Environ. Contam. Toxicol. 49(1) , 71-7, (1992)]
Fixed drug eruption due to citiolone.
1995-11-01
[Contact Dermatitis 33(5) , 352, (1995)]